Indivior Pharmaceuticals, Inc.（INDV）重大事項與業績發布
即將到來
- 2026-10-29 財報發布 推估
| 申報日 | 表別 | 事項 | 原文 |
|---|---|---|---|
| 2026-08-03 | 8-K | 重大契約、Reg FD 揭露、財務報表與附件 | SEC |
| 2026-08-03 | 8-K | 業績發布、Reg FD 揭露、財務報表與附件 | SEC |
| 2026-08-03 | 8-K | Reg FD 揭露、財務報表與附件 | SEC |
| 2026-05-15 | 8-K | 董事與高階主管異動、股東會表決結果 | SEC |
| 2026-05-04 | 8-K | Reg FD 揭露、其他事項、財務報表與附件 | SEC |
| 2026-04-30 | 8-K | 業績發布、Reg FD 揭露、財務報表與附件 | SEC |
| 2026-03-17 | 8-K | 重大契約、契約終止、直接財務義務、未登記股票銷售、財務報表與附件 | SEC |
| 2026-03-13 | 8-K | 其他事項、財務報表與附件 | SEC |
| 2026-03-12 | 8-K | 其他事項、財務報表與附件 | SEC |
| 2026-02-26 | 8-K | 業績發布、Reg FD 揭露、財務報表與附件 | SEC |
| 2026-01-26 | 8-K | 重大契約、直接財務義務、未登記股票銷售、Item 3.03、控制權變更、董事與高階主管異動、章程修訂、Item 5.05、Reg FD 揭露、其他事項、財務報表與附件 | SEC |
| 2026-01-08 | 8-K | Reg FD 揭露、財務報表與附件 | SEC |
| 2025-12-22 | 8-K | Reg FD 揭露、財務報表與附件 | SEC |
| 2025-12-18 | 8-K | 董事與高階主管異動 | SEC |
| 2025-12-15 | 8-K | 章程修訂、股東會表決結果、財務報表與附件 | SEC |
| 2025-11-20 | 8-K | 契約終止、Reg FD 揭露、財務報表與附件 | SEC |
| 2025-11-14 | 8-K | Reg FD 揭露、財務報表與附件 | SEC |
| 2025-10-30 | 8-K | 業績發布、Reg FD 揭露、財務報表與附件 | SEC |
| 2025-10-01 | 8-K | Reg FD 揭露、財務報表與附件 | SEC |
| 2025-08-26 | 8-K | Item 2.05 | SEC |
| 2025-08-22 | 8-K | 董事與高階主管異動、財務報表與附件 | SEC |
| 2025-07-31 | 8-K | 業績發布、Reg FD 揭露、財務報表與附件 | SEC |
| 2025-06-30 | 8-K | Reg FD 揭露、財務報表與附件 | SEC |
| 2025-06-24 | 8-K | 董事與高階主管異動、其他事項、財務報表與附件 | SEC |
| 2025-06-02 | 8-K | Reg FD 揭露、財務報表與附件 | SEC |
| 2025-06-02 | 8-K | 其他事項、財務報表與附件 | SEC |
| 2025-05-08 | 8-K | 董事與高階主管異動、章程修訂、股東會表決結果、Reg FD 揭露、財務報表與附件 | SEC |
| 2025-04-24 | 8-K | 業績發布、財務報表與附件 | SEC |
| 2025-03-27 | 8-K | Reg FD 揭露、財務報表與附件 | SEC |
| 2025-03-04 | 8-K | 重大契約、董事與高階主管異動、財務報表與附件 | SEC |
| 2025-03-03 | 6-K | TOTAL VOTING RIGHTS | SEC |
| 2025-02-28 | 6-K | HOLDING(S) IN COMPANY | SEC |
| 2025-02-28 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2025-02-28 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2025-02-27 | 6-K | JOSEPH CIAFFONI APPOINTED CHIEF EXECUTIVE OFFICER | SEC |
| 2025-02-27 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2025-02-27 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2025-02-25 | 6-K | HOLDING(S) IN COMPANY | SEC |
| 2025-02-24 | 6-K | FDA APPROVAL OF SUBLOCADE LABEL CHANGES | SEC |
| 2025-02-20 | 6-K | — | SEC |
| 2025-02-12 | 6-K | DELAYED FDA APPROVAL OF SUBLOCADE LABEL CHANGES | SEC |
| 2025-02-04 | 6-K | TRANSACTION IN OWN SHARES | SEC |
| 2025-02-04 | 6-K | COMPLETION OF SHARE REPURCHASE PROGRAM | SEC |
| 2025-02-04 | 6-K | NOTICE OF RESULTS | SEC |
| 2025-02-03 | 6-K | APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR | SEC |
| 2025-02-03 | 6-K | TOTAL VOTING RIGHTS | SEC |
| 2025-01-28 | 6-K | TRANSACTION IN OWN SHARES | SEC |
| 2025-01-28 | 6-K | HOLDING(S) IN COMPANY | SEC |
| 2025-01-28 | 6-K | DR. DAVID WHEADON APPOINTED CHAIR OF THE BOARD | SEC |
| 2025-01-27 | 6-K | HOLDING(S) IN COMPANY | SEC |
| 2025-01-21 | 6-K | TRANSACTION IN OWN SHARES | SEC |
| 2025-01-14 | 6-K | TRANSACTION IN OWN SHARES | SEC |
| 2025-01-10 | 6-K | INDIVIOR PROVIDES HISTORICAL FINANCIALS IN US GAAP | SEC |
| 2025-01-07 | 6-K | TRANSACTION IN OWN SHARES | SEC |
| 2025-01-07 | 6-K | HOLDING(S) IN COMPANY | SEC |
| 2025-01-02 | 6-K | TOTAL VOTING RIGHTS | SEC |
| 2024-12-31 | 6-K | TRANSACTION IN OWN SHARES | SEC |
| 2024-12-31 | 6-K | HOLDING(S) IN COMPANY | SEC |
| 2024-12-26 | 6-K | TRANSACTION IN OWN SHARES | SEC |
| 2024-12-23 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
資料來自 SEC EDGAR 的 8-K／6-K 申報。8-K 是美國國內發行人的重大事項揭露（Item 2.02 為業績發布）；6-K 是外國發行人（含 ADR）的對應形式。本站僅整理連結，原文一律在 SEC 網站。